# Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

> **NCT04925479** · PHASE1,PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 34 (estimated)

## Conditions studied

- Myeloid Leukemia, Philadelphia Positive

## Interventions

- **DRUG:** Asciminib Pediatric formulation group
- **DRUG:** Asciminib Adult formulation group

## Key facts

- **NCT ID:** NCT04925479
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-27
- **Primary completion:** 2026-06-16
- **Final completion:** 2031-11-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925479, "Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04925479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*